Future Financial Wealth Managment LLC Buys 753 Shares of Pfizer Inc. (NYSE:PFE)

Future Financial Wealth Managment LLC raised its position in Pfizer Inc. (NYSE:PFE) by 5.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,133 shares of the biopharmaceutical company’s stock after purchasing an additional 753 shares during the quarter. Future Financial Wealth Managment LLC’s holdings in Pfizer were worth $375,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. GHP Investment Advisors Inc. raised its position in shares of Pfizer by 5.2% in the 2nd quarter. GHP Investment Advisors Inc. now owns 12,589 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 620 shares in the last quarter. Parallel Advisors LLC increased its position in Pfizer by 19.1% during the 2nd quarter. Parallel Advisors LLC now owns 108,180 shares of the biopharmaceutical company’s stock valued at $3,027,000 after buying an additional 17,370 shares in the last quarter. Thoroughbred Financial Services LLC raised its stake in Pfizer by 102.9% in the second quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock valued at $900,000 after buying an additional 16,313 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Pfizer by 9.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 328,170 shares of the biopharmaceutical company’s stock worth $9,182,000 after acquiring an additional 27,178 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Pfizer by 2.4% during the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock valued at $287,077,000 after acquiring an additional 238,850 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE traded down $0.04 on Monday, hitting $26.68. 18,345,813 shares of the company’s stock were exchanged, compared to its average volume of 33,025,199. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market cap of $151.20 billion, a price-to-earnings ratio of 36.05, a P/E/G ratio of 0.63 and a beta of 0.64. The firm has a 50-day moving average price of $26.18 and a 200-day moving average price of $28.04. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.45%. Pfizer’s dividend payout ratio (DPR) is 232.43%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.